Company Description
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases.
The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections.
The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases.
The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas.
In addition, it is involved in the operation of medical clinics. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017.
Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited operates as a subsidiary of Jurchen Investment Corporation.
| Country | United Kingdom |
| IPO Date | Dec 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Chung Yuen Huen |
Contact Details
Address: 17 Hanover Square London, X0 W1S 1BN United Kingdom | |
| Phone | 852 3953 7700 |
| Website | aptorumgroup.com |
Stock Details
| Ticker Symbol | APM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001734005 |
| CUSIP Number | G6096M106 |
| ISIN Number | KYG6096M1226 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chung Yuen Huen | Founder, Chief Executive Officer and Non-Executive Director |
| Martin Siu | Head of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 22, 2023 | 6-K | Report of foreign issuer |
| Dec 21, 2023 | 6-K | Report of foreign issuer |
| Nov 30, 2023 | 6-K | Report of foreign issuer |
| Nov 21, 2023 | 6-K/A | Filing |